Device Trial Radar · NCT05198674
SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN
Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,899
Actual
Start
Oct 20, 2021
Primary completion
Mar 5, 2026
Study completion Nov 30, 2029
Sponsor
- Lead sponsor
- Medtronic VascularPublic (MDT)
- Sponsor type
- Industry
- First posted
- Jan 20, 2022
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this single-arm interventional study is to evaluate the long-term safety, efficacy, and durability of the Symplicity Spyral system in subjects treated with renal denervation. Additionally, long-term follow-up data will also be collected from eligible subjects previously treated in the SPYRAL PIVOTAL-SPYRAL HTN-OFF MED and SPYRAL HTN-ON MED studies.
Conditions
- Hypertension
- Vascular Diseases
- Cardiovascular Diseases
- Chronic Kidney Diseases
- Diabetes Mellitus
Interventions
Renal Denervation (Symplicity Spyral™)Device
Device: Symplicity Spyral™ multi-electrode renal denervation system. After a renal angiography according to standard procedures, subjects are treated with the renal denervation procedure.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Primary endpoint of office Systolic Blood Pressure (SBP) change at 6 months.Time frame: 6 months
Locations
97 sites in 11 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham (UAB) Hospital
Birmingham, Alabama
Banner Heart Hospital
Mesa, Arizona
Abrazo Arizona Heart Hospital/Biltmore Cardiology
Phoenix, Arizona
94 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.